Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 6/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21670417 | 0.73 | CYP11B2 (0.48) | CYP11B2 | |
| SCHEMBL24328697 | 0.70 | TP53 (0.31) | — | |
| SCHEMBL24328037 | 0.70 | CYP11B2 (0.50) | CSNK2A2CSNK2BCSNK2A1ABCG2CYP11B2 | |
| SCHEMBL24683711 | 0.67 | — | — | |
| SCHEMBL26377790 | 0.66 | CSNK2A2 (0.35) | CSNK2A2CSNK2BCSNK2A1CSNK2A3ABCG2 | |
| SCHEMBL26380716 | 0.66 | CSNK2A2 (0.35) | CSNK2A2CSNK2BCSNK2A1CSNK2A3ABCG2 | |
| SCHEMBL24329230 | 0.63 | MAPK14 (0.36) | SMN1; SMN2KDM4EPIK3CAHTT | |
| SCHEMBL18762232 | 0.61 | ADORA2A (0.32) | — | |
| SCHEMBL21670416 | 0.60 | KDM4E (0.31) | KDM4EKMT2A | |
| SCHEMBL21670414 | 0.60 | KDM4E (0.31) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312583-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230312583-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| WO-2022042676-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-03-03 | — | — | WO | disclosed |
| EP-3608321-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2020-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312583-A1 | 1H-IMIDAZO [4,5-H] QUINAZOLINE COMPOUND AS NOVEL SELECTIVE FLT3 INHIBITORS | FLT3, ABL1, FLI1 | POLB 2869/4885GRM5 2324/4885CSNK2A2 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.